May 25, 2017 11:36 AM ET

Life Sciences Tools and Services

Company Overview of Mytrus, Inc.

Company Overview

Mytrus, Inc. is an e-clinical technology company that specializes in patient-centered electronic informed consent and data collection tools. The company develops remote electronic consent and virtual data collection solutions for running clinical trials. Its technologies for patients include ePRO and EDC tools, bio-sample consent tracking technology, site training and e-learning applications, and patient home dashboards for tracking clinical study progress and data. The company also holds a patent for conducting virtual clinical trials in the United States. Its patient-centered technologies enable people to participate in clinical trials. The company was founded in 2009 and is based in Davis...

105 East Street

Suite 2B

Davis, CA 95616

United States

Founded in 2009



Key Executives for Mytrus, Inc.

Co-Founder and Chief Executive Officer
Co-Founder, Chairman, Chief Scientific Officer and Member of Innovation Advisory Board
Director of Business Development
Vice President of Product Development and Engineering
Director of Client Services
Compensation as of Fiscal Year 2016.

Mytrus, Inc. Key Developments

Britain's National Health Service Approves the Use of Mytrus Technology for Electronic Informed Consent in Clinical Trials

Mytrus announced that its software platform for electronic informed consent has received approval for use by Britain's National Health Service (NHS). It is the first time e-Consent technology will be used in a trial in England. Mytrus was also the first electronic informed consent technology approved for use in a clinical trial by the U.S. Food and Drug Administration in 2011. It has since been used by some of the world's largest pharmaceutical companies in about 30 studies and received approvals from other national health authorities, as well as 50 institutional review boards and ethics committees. inVentiv Health is an investor in Mytrus and integrates its pioneering technology to help clients improve clinical trial execution, speed time to market and reduce product development costs. Approval for the use of Mytrus' electronic informed consent in the trial in England was granted by the Health Research Authority (HRA), a division of Britain's NHS. Mytrus' Enroll® 2.0 iOS software platform uses a tablet device to give potential participants a trial overview that includes simple, entertaining videos to reinforce key information. People read the informed consent document, answer questions to assess understanding and are prompted to review information they don't understand as well. Research site staff can track patient metrics to better understand where patients need counseling and dedicate time for each potential study participant to discuss the study with site staff before agreeing to sign consent. The study using Mytrus' Enroll® 2.0 iOS software platform and web portal began enrolling patients in July. It is being conducted by a top-ten, global pharmaceutical company to determine the safety of a new investigational drug. The e-Consent pilot is being run in tandem with traditional paper consent so that results can be compared. An independent study conducted by the California Pacific Medical Center Research Institute using Enroll® found that patients provided with paper-only consent were able to correctly answer 58% of the questions asked on a follow up questionnaire, versus those who used an electronic consent application could correctly answer 75% of the questions. Drug companies seeking ways to manage soaring development costs can look to Mytrus technology to increase efficiency and improve the patient enrollment experience. In addition, Mytrus' Enroll® provides a variety of significant benefits in improving site performance, with the ability to expedite study start times and enhance regulatory compliance. The technology provides insights to improve relationship management with trial sites and allow sponsors to offer richer, deeper information to regulatory authorities at every step on the path from trial to commercialization. Mytrus technology has been used by 8 out of the world's 10 large pharmaceutical companies to improve patient enrollment in clinical trials. Most recently, Mytrus was selected for a pilot project by the oncology clinics at New York-Presbyterian/Weill Cornell Medical Center's Joint Clinical Trials Office. They will use Mytrus' Enroll® to streamline the enrollment process for doctors and researchers and enable them to track consent status for future research.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

April 17, 2017

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Mytrus, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at